TWO · 7427.TWO
Great Novel Therapeutics Biotech & Medicals
NT$64.00+NT$0.90 (+1.43%)
Great Novel Therapeutics Biotech & Medicals’s quoted price sits in the upper half of its reported 52-week range, 22.71% below the high.
Loading market information…
TWO · 6827.TWO · TWD
Stock price
Quote as of Oct 30, 2026, 06:59 AM UTC. Cached market data; not a live quote.
One-year closing-price history · TWD. Historical prices are not a forecast.
MegaPro Biomedical Co., Ltd’s quoted price sits in the upper half of its reported 52-week range, 19.06% below the high.
52-week range
Go beyond this overview with deeper company research in PortfolioX. Explore more in the app
THE COMPANY BEHIND THE TICKER
MegaPro Biomedical Co., Ltd. operates as a biotechnology enterprise primarily focused on pioneering nanodrugs. Its innovative development pipeline includes MPB-1523, an IOP injection currently in Phase II clinical evaluation for addressing hepatocellular carcinoma. Simultaneously, MPB-1514, an iron injection, is also undergoing Phase II clinical trials, targeting iron deficiency anemia. Furthermore, the firm is advancing MPB-1734, an anti-cancer pharmaceutical, which is in preclinical assessment for the treatment of malignant tumors. Established in 2014, this company is headquartered in Zhubei, Taiwan.
Latest available per-share figures in TWD. The payout ratio compares dividends with earnings.
About this data · PortfolioX market data, also available in the mobile app. Prices are displayed in the listing currency; dividend amounts use the currency shown in that section. Data availability and update times vary.
Page generated Oct 30, 2026, 11:27 AM UTC. Quotes retain their own timestamp above. Missing values appear as a dash. This page is for information only, not personalized investment advice.
HOW THE BUSINESS IS PERFORMING
Statement amounts use the company’s reporting currency and are not converted to the stock’s listing currency. K = thousand, M = million, B = billion, T = trillion. Cash-flow figures are matched by fiscal year; missing figures appear as a dash.
PUT THE NUMBERS IN CONTEXT
Current metrics alongside available historical medians. A lower multiple or higher margin alone does not establish whether a stock is a good investment.
KEEP COMPARING
NT$64.00+NT$0.90 (+1.43%)
Great Novel Therapeutics Biotech & Medicals’s quoted price sits in the upper half of its reported 52-week range, 22.71% below the high.
NT$18.70-NT$0.15 (-0.8%)
NaviFUS Corp.’s quoted price sits in the lower half of its reported 52-week range, 30.87% below the high.
NT$31.45-NT$0.05 (-0.16%)
NeoCore Technology Co., Ltd.’s quoted price sits in the lower half of its reported 52-week range, 25.91% below the high.
NT$22.55-NT$0.35 (-1.53%)
Bio Preventive Medicine Corp.’s quoted price sits in the lower half of its reported 52-week range, 50.98% below the high.
NT$23.00NT$0.00 (0.0%)
LabTurbo Biotech Corporation’s quoted price sits in the lower half of its reported 52-week range, 11.88% below the high.
NT$14.90-NT$0.40 (-2.61%)
Enimmune corporation’s quoted price sits in the lower half of its reported 52-week range, 33.92% below the high.
NT$13.95-NT$0.05 (-0.36%)
LAUNXP Biomedical Co., Ltd’s quoted price sits in the lower half of its reported 52-week range, 45.19% below the high.
NT$16.35-NT$0.30 (-1.8%)
GeneReach Biotechnology Corp.’s quoted price sits in the lower half of its reported 52-week range, 36.99% below the high.
